Mature ‘fit-for-purpose’ methods and approaches with good commercial perspectives and significant impact on the numbers of animals used in research, product development, and efficacy and safety assessment are of interest.
Investment is considered after evaluation of the proposed business and financial plans.
Examples include SenzaGen BV (Lund, Sweden), ToxGenSolutions BV (Maastricht, Netherlands), PreMeDia (Hangzhou, China).